SCHEMBL4066746

SCHEMBL4066746

O=S(O)c1cnc2cc(-c3ccc(F)cc3)ccc2c1.[NaH]

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 3/20 0.40
PDGFRA P16234 3/20 0.40
ESR2 Q92731 1/20 0.39
HTR2C P28335 1/20 0.36
MCHR1 Q99705 1/20 0.36
CSF1R P07333 3/20 0.36
GRIN2B Q13224 4/20 0.34
PIK3CA P42336 3/20 0.34
MTOR P42345 3/20 0.34
PGR P06401 1/20 0.34
PIK3CD O00329 1/20 0.34
GRIN1 Q05586 1/20 0.33
MAP4K4 O95819 1/20 0.33
TNIK Q9UKE5 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4066742 0.83 PDGFRB (0.40) PDGFRBPDGFRAESR2HTR2CMCHR1
SCHEMBL4070877 0.79 PGR (0.42) ESR2PGR
SCHEMBL26549437 0.76 PDGFRB (0.61) PDGFRBPDGFRAESR2PIK3CAMTOR
SCHEMBL26549163 0.76 PDGFRB (0.61) PDGFRBPDGFRAESR2PIK3CAMTOR
SCHEMBL4069703 0.72 PDGFRB (0.45) PDGFRBPDGFRAESR2HTR2CMCHR1
SCHEMBL26549330 0.70 PDGFRB (0.54) PDGFRBPDGFRAESR2PIK3CAMTOR
SCHEMBL26570966 0.70 PDGFRB (0.54) PDGFRBPDGFRAESR2GRIN2BPIK3CA
SCHEMBL26549071 0.70 PDGFRB (0.58) PDGFRBPDGFRAESR2PIK3CAMTOR
SCHEMBL26549030 0.70 PDGFRB (0.54) PDGFRBPDGFRAESR2PIK3CAMTOR
SCHEMBL26549364 0.70 PDGFRB (0.58) PDGFRBPDGFRAESR2PIK3CAMTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592456-B2 Arylsulfonylnaphthalene derivatives as 5HT2A antagonists MERCK SHARP & DOHME LIMITED (GB) 2009-09-22 US disclosed
EP-1824817-B1 ARYLSULFONYLNAPHTHALENE DERIVATIVES AS 5HT2A ANTAGONISTS MERCK SHARP & DOHME (GB) 2009-02-04 EP disclosed
US-20070281952-A1 Arylsulfonylnaphthalene Derivatives As 5Ht2a Antagonists MERCK SHARPE & DOHME LIMITED (GB) 2007-12-06 US disclosed
CN-101068776-A As 5HT2AArylsulfonyl naphthalene derivatives as antagonists MERCH SHARP & DOHME LTD (GB) 2007-11-07 CN disclosed
EP-1824817-A1 ARYLSULFONYLNAPHTHALENE DERIVATIVES AS 5HT2A ANTAGONISTS MERCK SHARP & DOHME LTD. (GB) 2007-08-29 EP disclosed
WO-2006059149-A1 ARYLSULFONYLNAPHTHALENE DERIVATIVES AS 5HT2A ANTAGONISTS MERCK SHARP & DOHME LIMITED (GB) 2006-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281952-A1 Arylsulfonylnaphthalene Derivatives As 5Ht2a Antagonists HTR2A, HTR2C, HTR1A PDGFRB 366/4885PDGFRA 363/4885ESR2 610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.